Research

RNA-binding proteins, primary prostate tumours, population-based analyses in diagnostics

Interests

He is one of only a handful of academic surgeons in the UK to be awarded the RCSEng/CR-UK Clinician Scientist Fellowship in Surgery, which supports a laboratory-based research programme at Barts Cancer Institute, Queen Mary University of London. Work in his laboratory focusses on how key genetic changes in prostate cancer cells allow them to become resistant to various treatments and spread to other parts of the body.

Publications

Publications of specific relevance to Applied Data Science

2020

Thompson JE, Sridhar AN, Shaw G, Rajan P, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD and Sooriakumaran P (2020). Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation. Bmc Urology  vol. 20, (1) 10.1186/s12894-020-00656-9

Lauria A, Peirone S, Giudice MD, Priante F, Rajan P, Caselle M, Oliviero S and Cereda M (2020). Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Nucleic Acids Research  vol. 48, (4) 1730-1747. 10.1093/nar/gkz1208

Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Shaw G and Lu YJ (2020). Reply by Authors. The Journal of Urology  vol. 203, (1) 81-82. 10.1097/01.JU.0000602796.11621.76

Sehmbi AS, Sridhar AN, Sahadevan K, Rai BP, Nwangwu P, Mohammed A, Freeman A, Mottrie A, Olsson MJ, Wiklund NP, Nathan MS, Briggs TP, Kelly JD and Rajan P (2020). Early outcomes of robot-assisted radical prostatectomy following completion of a structured training curriculum: a single surgeon cohort study. Journal of Clinical Urology  10.1177/2051415820938176

2019

De Laere B, Crippa A, Ghysel C, Ost P, Rajan P, Eklund M, Dirix L, Grönberg H and Lindberg J (2019). 106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer. Annals of Oncology  vol. 30, (Supplement_5) v30-v31. 10.1093/annonc/mdz239.017

Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Shaw G and Lu Y-J (2019). Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. The Journal of Urology  vol. 203, 101097JU000-101097JU000. 10.1097/JU.0000000000000475

Thompson JE, Sridhar AN, Tan WS, Freeman A, Haider A, Allen C, Moore CM, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD and Sooriakumaran P (2019). Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol  vol. 201, (6) 1134-1143. 10.1097/JU.0000000000000135

De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J and CORE-ARV-CTC and ProBIO Investigators (2019). Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. Jama Oncol  10.1001/jamaoncol.2019.0869

Heavey S, Costa H, Pye H, Burt EC, Jenkinson S, Lewis GR, Bosshard-Carter L, Watson F, Jameson C, Ratynska M, Ben-Salha I, Haider A, Johnston EW, Feber A, Shaw G, Sridhar A, Nathan S, Rajan P, Briggs TP, Sooriakumaran P, Kelly JD, Freeman A and Whitaker HC (2019). PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens. Prostate  vol. 79, (7) 768-777. 10.1002/pros.23782

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Favero JD, Rantalainen M and Rajan P (2019). TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clinical Cancer Research  vol. 25, (6) 1766-1773. 10.1158/1078-0432.CCR-18-1943

2018

Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, Van Dam PJ, Van Den Eynden G, Rutten A, Aly M, Nordström T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullén A, Yachnin J and Dirix L (2018). Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine  vol. 10, (1) 10.1186/s13073-018-0595-5

Munkley J, Maia TM, Ibarluzea N, Livermore KE, Vodak D, Ehrmann I, James K, Rajan P, Barbosa-Morais NL and Elliott DJ (2018). Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. F1000 Research Ltd  F1000research  vol. 7, 1189-1189. 10.12688/f1000research.15604.1

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang T-Y, Shaw PE, Reynolds LE, McKay TR, Wang H-W, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I and Sharp TV (2018). A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia. Embo Mol Med  10.15252/emmm.201708304

Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G and Wiklund NP (2018). Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus  vol. 4, (3) 351-359. 10.1016/j.euf.2016.10.007

Lamb BW and Rajan P (2018). The practicing urologists’ guide to clinical research. Journal of Clinical Urology  10.1177/2051415818761528

2017

Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G and Wiklund NP (2017). Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol  vol. 35, (31) 3566-3574. 10.1200/JCO.2016.70.7794

Munkley J, Livermore K, Rajan P and Elliott DJ (2017). RNA splicing and splicing regulator changes in prostate cancer pathology. Human Genetics  vol. 136, (9) 1143-1154. 10.1007/s00439-017-1792-9

Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Mills IG, Robson CN, Rajan P and Elliott DJ (2017). The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Macmillan Publishers Limited, Part of Springer Nature  Sci Rep  vol. 7, (1) 5249-5249. 10.1038/s41598-017-05489-5

2016

Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P and Elliott DJ (2016). Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. Elsevier: Creative Commons  Ebiomedicine  10.1016/j.ebiom.2016.04.018

2015

Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY and Rajan P (2015). The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Sci Rep  vol. 5, 10.1038/srep13426

Rajan P, Frew JA, Wilson JM, Azzabi AST, McMenemin RM, Stockley J, Soomro NA, Durkan G, Pedley ID and Leung HY (2015). Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol  vol. 33, (8) 337.e1-337.e6. 10.1016/j.urolonc.2015.05.012

Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P and Elliott DJ (2015). Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. Bmc Cancer  vol. 15, 10.1186/s12885-015-1012-8

Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG and Elliott DJ (2015). The androgen receptor controls expression of the cancerassociated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget  vol. 6, (33) 34358-34374. 10.18632/oncotarget.6024

Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M, Leung HY, Robson CN, Harries LW, Rajan P and Elliott DJ (2015). The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience  vol. 2, (9) 755-764. 10.18632/oncoscience.243

2014

Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID and Leung HY (2014). Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. Bmc Cancer  vol. 14, 10.1186/1471-2407-14-977

Rajan P, Sudbery IM, Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID and Leung HY (2014). Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol  vol. 66, (1) 32-39. 10.1016/j.eururo.2013.08.011

Munkley J, Rajan P, Lafferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY and Elliott DJ (2014). A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget  vol. 5, (1) 131-139. 10.18632/oncotarget.1405

Lamb BW and Rajan P (2014). Clinical Research Toolkit for Urologists. Journal of Clinical Urology  vol. 9, (3) 10.1177/2051415816632390

Stockley J, Villasevil MEM, Nixon C, Ahmad I, Leung HY and Rajan P (2014). The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer. Rna Biol  vol. 11, (6) 755-765. 10.4161/rna.28800

2008

Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY and Elliott DJ (2008). The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol  vol. 215, (1) 67-77. 10.1002/path.2324

Grants

Grants of specific relevance to Applied Data Science

Sam68 and hnRNPA2 in prostate cancer
Rajan P
£800,000 Cancer Research UK (01-05-2013 - 30-01-2020)

Summary